ttk Antibody

What is TTK protein and what cellular functions does it regulate?

TTK (also known as Mps1) is a dual specificity threonine/tyrosine kinase that functions as a critical cell cycle regulator. It belongs to the serine-threonine/tyrosine family of protein kinases and participates in several essential cellular processes:

• Regulation of chromosome alignment and spindle assembly checkpoint signaling

• Centrosome duplication

• Repair of incorrect mitotic kinetochore-spindle microtubule attachments

• DNA damage response pathway activation

TTK expression is highest in proliferating tissues and fluctuates during the cell cycle, with levels increasing from G1 to S phase and peaking during G2 to M phase transition . This expression pattern suggests TTK functions as a critical cell cycle regulatory component. In resting cells or those with low proliferative indices, TTK expression is notably reduced or absent .

What applications are TTK antibodies validated for?

TTK antibodies have been validated for multiple laboratory applications with varying dilution recommendations:

Most commercial TTK antibodies react with human samples, though some have confirmed reactivity with mouse and rat tissues . Researchers should verify species reactivity for their specific experimental system.

What is the expected molecular weight and localization pattern for TTK?

TTK protein has a calculated molecular weight of 97 kDa, and antibodies typically detect bands at approximately 95-100 kDa in Western blot applications . In human cells, TTK predominantly displays cytoplasmic and membrane staining patterns (observed in 99.4% of samples in one study), while approximately 5.9% of cases may show additional nuclear expression .

Immunofluorescence studies typically reveal cytoplasmic localization with potential membrane association. In cancer specimens, TTK has been detected in plasma membranes of epithelial cells as demonstrated in human squamous cell carcinoma samples .

How should I design experiments to study TTK's role in cancer progression?

When designing experiments to study TTK's role in cancer:

What are the recommended protocols for TTK antibody validation?

Thorough validation of TTK antibodies should include:

• Western blot analysis with positive control cell lines:

  • A431 human epithelial carcinoma

  • HeLa human cervical epithelial carcinoma

  • MCF-7 human breast cancer

  • DU 145 prostate cancer cells

  • HepG2 human liver cancer cells

• Knockdown/knockout validation:

  • siRNA against TTK to confirm antibody specificity

  • Compare with control siRNA (e.g., vimentin siRNA as shown in one study)

• Cross-reactivity testing:

  • Test across multiple species if cross-reactivity is claimed

  • Examine potential cross-reactivity with related kinases

• Immunoprecipitation validation:

  • IP with anti-TTK antibody followed by Western blot with a second antibody targeting a different epitope

  • Compare with normal IgG control IP

• Peptide competition assay:

  • Pre-incubation with immunizing peptide should abolish specific signal

Multiple antibody clones (monoclonal and polyclonal) are available, each with specific validation data that should be reviewed before selection for your experiment .

How do I reconcile contradictory findings regarding TTK as a prognostic biomarker in different cancer types?

The prognostic significance of TTK varies across cancer types, requiring careful interpretation:

To reconcile these seemingly contradictory findings:

• Consider cancer-specific molecular contexts: TTK may interact with different pathways depending on tumor type.

• Analyze expression methodology differences: Studies use various techniques (IHC, RNA-seq, microarray) with different thresholds for defining "high" expression.

• Evaluate subcellular localization patterns: Nuclear versus cytoplasmic expression may have distinct implications (5.9% of TNBC samples showed nuclear staining, which might affect function) .

• Examine cohort characteristics: Patient demographics, treatment history, and molecular subtypes within each cancer type influence outcomes.

• Design integrative studies: Combine TTK expression with other molecular markers for improved prognostic value.

When studying a new cancer type, it's advisable to conduct a comprehensive analysis correlating TTK expression with clinicopathological features and survival outcomes specific to that cancer.

What are the best methods for studying TTK-mediated phosphorylation events?

To investigate TTK-mediated phosphorylation:

• Phospho-specific antibodies: Use antibodies targeting known TTK phosphorylation sites on substrates (e.g., Chk2 at Thr68) .

• In vitro kinase assays:

  • Immunoprecipitate TTK using validated antibodies

  • Incubate with recombinant substrates and ATP

  • Detect phosphorylation by Western blot with phospho-specific antibodies

• Phosphoproteomics approach:

  • Compare phosphopeptide profiles in control vs. TTK-inhibited/depleted cells

  • Enrich phosphopeptides using TiO2 or IMAC methods

  • Analyze by mass spectrometry to identify TTK-dependent phosphorylation sites

• Functional validation:

  • Generate phospho-mimetic (S/T to D/E) and phospho-deficient (S/T to A) mutants

  • Test functional consequences in cell cycle progression assays

• Temporal analysis:

  • Synchronize cells and collect samples at different cell cycle stages

  • Monitor TTK activity and substrate phosphorylation throughout the cell cycle

Known TTK substrates include MAD1L1, CDCA8/Borealin (enhancing AURKB activity), SKA3 (at Ser-34), KNL1, KNTC1, and p53 .

How can I optimize immunofluorescence protocols for detecting TTK in fixed cells?

For optimal TTK immunofluorescence staining:

• Cell fixation options:

  • 4% paraformaldehyde (most common)

  • Methanol fixation may better preserve some epitopes

• Permeabilization:

  • 0.1-0.5% Triton X-100 in PBS for 10 minutes

  • Alternative: 0.5% saponin for gentler permeabilization

• Blocking conditions:

  • 10% normal goat serum (or serum matching secondary antibody species)

  • Include in blocking buffer: 1% BSA, 0.3% Triton X-100 in PBS

• Antibody incubation:

  • Primary antibody: Use at 2 μg/mL concentration

  • Overnight incubation at 4°C yields best results

  • Secondary antibody: DyLight 488-conjugated anti-rabbit/mouse IgG at 1:100-1:500 dilution

• Co-staining options:

  • Combine with cell cycle markers (e.g., cyclin B1)

  • Use DAPI for nuclear counterstaining

• Validated controls:

  • A431 cells show reliable TTK staining patterns

  • Include antibody specificity controls (TTK knockdown cells)

• Image analysis:

  • Visualize using appropriate filter sets for the fluorophores

  • Evaluate subcellular localization (membrane, cytoplasmic, nuclear)

  • Quantify signal intensity across different cell cycle phases

One validated protocol used enzyme antigen retrieval with A431 cells, blocking with 10% goat serum, and incubation with 2 μg/mL anti-TTK antibody overnight at 4°C .

What are common challenges in Western blotting for TTK and how can they be resolved?

When detecting TTK by Western blot, researchers may encounter these challenges:

• Multiple bands/non-specific binding:

  • Increase blocking concentration (5% non-fat milk/TBS is effective)

  • Optimize primary antibody dilution (start with 1:1000)

  • Use freshly prepared lysates with complete protease inhibitors

  • Consider PVDF membrane which typically yields better results for TTK detection

• Weak or no signal:

  • Confirm TTK expression in your cell type (A431, HeLa, MCF-7 cells are positive controls)

  • Increase protein loading (50 μg lysate is often used in published protocols)

  • Optimize transfer conditions for high molecular weight proteins

  • Use reducing conditions for optimal TTK detection

• Inconsistent molecular weight:

  • TTK may appear between 95-105 kDa depending on phosphorylation state

  • Use fresh samples to avoid degradation products

  • Include molecular weight markers with precise sizing

• Validated protocols:

  • One established protocol uses A431, HepG2, or RAW264.7 cell lysates (50 μg)

  • SDS-PAGE: 5-20% gradient gel at 70V (stacking)/90V (resolving)

  • Transfer: 150mA for 50-90 minutes to nitrocellulose

  • Blocking: 5% non-fat milk in TBS for 1.5 hours

  • Primary antibody: 0.5 μg/mL overnight at 4°C

  • Washing: TBS with 0.1% Tween, 3 times, 5 minutes each

  • Secondary antibody: Anti-rabbit IgG-HRP at 1:5000 dilution

How can I determine the specificity of my TTK antibody in immunohistochemistry applications?

To verify TTK antibody specificity in IHC:

• Peptide competition assay:

  • Pre-incubate antibody with excess immunizing peptide

  • Parallel staining should show elimination of specific signal

• Comparison with knockdown tissue/cell blocks:

  • Generate FFPE blocks of TTK-knockdown and control cells

  • Process alongside experimental samples

• Multi-antibody validation:

  • Use antibodies recognizing different TTK epitopes

  • Compare staining patterns for consistency

• Tissue panel verification:

  • Test known positive tissues (testicular tissue, rectal cancer, intestine)

  • Include negative controls (tissues with minimal proliferation)

• Heat-mediated antigen retrieval optimization:

  • Test both EDTA buffer (pH 8.0) and citrate buffer (pH 6.0)

  • Different TTK epitopes may require specific retrieval conditions

• Blocking and detection system optimization:

  • 10% goat serum has been validated for blocking

  • For detection, Strepavidin-Biotin-Complex (SABC) with DAB works effectively

• Semi-quantitative assessment:

  • Consider using the H-score system that accounts for both staining intensity and percentage of positive cells

  • This provides more robust evaluation than intensity alone

What considerations are important when designing TTK expression studies in patient samples?

When designing clinical studies of TTK expression:

• Patient cohort selection:

  • Define clear inclusion/exclusion criteria

  • Consider sample size calculations based on expected effect size

  • Document relevant clinical parameters (stage, grade, treatment history)

• Control tissue selection:

  • Adjacent normal tissue from same patient when possible

  • Match for demographic factors if using separate control cohorts

• Scoring methodology standardization:

  • Define and validate scoring system before analysis

  • Consider H-score method (intensity × percentage positive cells)

  • Set threshold values using ROC curve analysis (e.g., H-score of 55 was optimal in TNBC study)

• Subcellular localization documentation:

  • Record cytoplasmic, membrane, and nuclear staining separately

  • Report percentages of different staining patterns (e.g., 5.9% of TNBC samples showed nuclear expression)

• Statistical analysis planning:

  • Pre-specify primary endpoints (OS, DFS, progression-free survival)

  • Plan appropriate statistical tests (log-rank for survival, Cox regression for multivariate analysis)

  • Consider multiple testing corrections for exploratory analyses

• Integration with molecular data:

  • Correlate with relevant molecular markers

  • Consider subgroup analyses by molecular subtypes

How might TTK antibodies be utilized in studying cancer immune interactions?

Recent data suggest TTK expression correlates with immune cell infiltration, opening new research directions:

• Immune infiltration correlation studies:

  • TTK mRNA expression has shown correlation with B cells and neutrophils in endometrial cancer

  • Analyze TTK expression alongside immune cell markers using multiplexed IHC or flow cytometry

• Tumor microenvironment analysis:

  • Use TTK antibodies in combination with immune checkpoint markers

  • Investigate spatial relationships between TTK-expressing cells and tumor-infiltrating lymphocytes

• Therapeutic response prediction:

  • Evaluate TTK expression as a potential biomarker for immunotherapy response

  • Correlate TTK levels with immunotherapy outcomes in retrospective cohorts

• Single-cell analysis applications:

  • Incorporate TTK antibodies in cytometry by time of flight (CyTOF) panels

  • Examine TTK expression heterogeneity and its relationship to immune cell populations

• Functional studies:

  • Investigate how TTK inhibition affects immune cell recruitment and function

  • Study effects of TTK modulation on antigen presentation and T cell recognition

Researchers can use tools like the Tumor Immune Estimation Resource (TIMER) and Tumor-Immune System Interaction Database (TISIDB) to explore correlations between TTK expression and immune infiltration patterns .

What are the emerging applications of TTK antibodies in understanding therapy resistance mechanisms?

TTK antibodies can be valuable tools for investigating therapy resistance:

• Cell cycle checkpoint adaptation:

  • Monitor TTK expression and activity in therapy-resistant versus sensitive cells

  • Study how TTK phosphorylation patterns change following treatment

• DNA damage response pathways:

  • TTK participates in DNA damage response by phosphorylating and activating Chk2

  • Investigate TTK's role in response to chemotherapy and radiation by immunostaining for both TTK and phospho-Chk2

• Kinase inhibitor resistance:

  • Examine TTK expression in cells with acquired resistance to targeted therapies

  • Use phospho-specific antibodies to track compensatory signaling pathway activation

• Cancer stem cell biology:

  • Analyze TTK expression in tumor-initiating cell populations

  • Correlate with stemness markers and therapeutic resistance patterns

• Combined targeted therapy strategies:

  • Use TTK antibodies to monitor response to TTK inhibitors

  • Study combination approaches targeting TTK and complementary pathways

These applications will advance understanding of TTK's role in treatment resistance and potentially identify new therapeutic vulnerabilities in resistant tumors.